New pancreatic cancer pill could reshape treatment as early trial results stun researchers

A new pancreatic cancer pill called Daraxonrasib has shown promise in early testing, with about 30% of patients seeing a positive response and 90% having their cancer either shrink or stop getting worse. The pill is designed to block multiple active cancer signals that help tumor cells grow. The clinical trial was led by the Dana-Farber Cancer Institute.